Nuvation Bio prices $250M convertible notes offering
Seeking Alpha ·
Global oncology company Nuvation Bio ( NUVB ) announced Friday the pricing of an upsized underwritten offering of $250M aggregate principal amount of 0.75% Convertible Senior Notes due 2032. The aggregate principal amount of the offering was increased from the previously announced
DYAX Investor Sentiment
Bullish (Long) 36% · Bearish (Short) 64%
332 participants
Related News
- Aker Solutions wins Cenovus White Rose field deal
- Yealink Upgrades Singapore Global Operational HQ and Opens New Customer Experience Center
- 군산조선소 매각 본계약 체결...내년 신조선 건조 추진
- 3 Profitable Stocks We Keep Off Our Radar
- SoftBank shares plunge 13% as OpenAI reportedly weighs IPO delay to 2027
- NewtekOne files for $650M mixed securities shelf offering